ADHD 2023 - Congress Programme

36 SCIENTIFIC PROGRAMME Saturday, 20 May 2023 P-21-008 The effect of mobile neurofeedback on the neuropsychological functions of ADHD children M. Shin, Republic of Korea B. Kim P-21-009 Does chewing a piece of gum reduce hyperactivity and inattention in ADHD children? H. Slama, Belgium C. Urbain P-21-010 Stakeholder-generated solutions to promote engagement and implementa- tion in evidence-based interventions for ADHD in school settings A. Steinberg, USA M. Dvorsky, L. Pfiffner P-21-011 Making behavioral parent raining more accessible: A pilot study on a brief per- sonalized parenting program for children with (subthreshold) ADHD and behavio- ral problems R. van Doornik, The Netherlands A. Groenman, S. van der Oord, B. van den Hoofdakker, T. Dekkers P-22 Guided Poster Tour 14:00–15:30 Onyx Lounge Pharmacological treatment, adolescents, adults I Chair: J. Buitelaar, The Netherlands P-22-001 Stimulants, benefits outweigh the risks?: A review C. Batista, Portugal J. Nogueira, J. Marta, C. Ramos P-22-002 Iron deficiency as a predictor of response for psychostimulant treatment in adults with ADHD: A case series S. Castro, Portugal A. Ponte, F. Ferreira P-22-003 Evaluation of prescribing of lisdexamfe- tamine as first-line stimulant medication in a national online ADHD service A. Gibbs, United Kingdom A. Chatziagorakis, S. Ilyas, A. Cross, C. Abbasian P-22-005 Association between individual Norepine- phrine Transporter (NET) availability and response to pharmacological therapy in adults with ADHD J. Huang, Germany N. Mauche, M. Strauß P-22-006 Risk factors for discontinuation of ADHD medication in adults: A Danish nation- wide population-based study K. Johannessen, Denmark P. Ishøy, T. Houmann, E. Levin, P. Thomsen P-22-007 Neuropsychological correlates of atten- tional arousal and attentional control: Differences in ADHD with and without sluggish cognitive tempo B. Krone, USA J. Newcorn, I. Ivanov, K. Schulz P-22-008 A proposed protocol for identification of consumers with ADHD and provision of pharmacological treatment in secure custodial settings J. Le, Australia A. Mashhood, A. Barker, J. Kasinathan P-22-009 Association between ADHD medication treatment and premature mortality in individuals with ADHD: A Swedish na- tionwide cohort study L. Li, Sweden L. Zhang, B. D’Onofrio, H. Larsson, Z. Chang P-22-010 Study on Chinese patent medicine of ADHD: A review S. Wang, China Z. Chen P-22-011 Effects of guanfacine in adults with ADHD: The second report H. Suzuki, Japan W. Hayashi, H. Uno, S. Seki, Y. Hanawa, D. Nakamura, Y. Iwami, T. Otowa, K. Sanada, A. Iwanami P-22-012 Chronotherapy in adult ADHD: Results from the PhASE study E. van Andel, The Netherlands D. Bijlenga, S. Vogel, A. Beekman, J. Kooij P-23 Guided Poster Tour 14:00–15:30 Onyx Lounge Pharmacological treatment, adolescents, adults II Chair: J. Newcorn, USA P-23-001 ADHD and learning disabilities in school- aged children: A clinical case D. Alves, Portugal T. Rocha, M. Moreira, S. Martins, B. Pinto